Stock events for Merck & Co., Inc. (MRK)
Several events have influenced Merck's stock price over the past six months. In Q1 2025, Merck reported adjusted EPS that beat analyst estimates, but revenues declined year-over-year, with Keytruda sales missing expectations and HPV vaccine sales decreasing in China. Shares jumped 5.7% after positive results from the Phase 3 HYPERION trial for WINREVAIR™. The stock trended up by 5.22% following an innovative breakthrough in Alzheimer's treatment, a recommendation from the European Medicines Agency's committee for Keytruda in head and neck cancer, and FDA approval for the subcutaneous use of KEYTRUDA QLEX. Merck's stock rose 7.7% after the Trump administration announced a new program to sell drugs directly to consumers. Analysts have recently downgraded Merck's rating from "buy" to "hold," with revised price targets. The stock has seen a 13.24% rise in the past week and a 4.47% increase over the last month, but experienced a 20.24% decrease over the last year.
Demand Seasonality affecting Merck & Co., Inc.’s stock price
Merck & Co., Inc. has a "Seasonality Profile" that tracks mean and median monthly returns to identify seasonal patterns in its stock performance. However, specific details regarding the seasonal demand patterns for its individual products and services are not publicly detailed in the provided search results.
Overview of Merck & Co., Inc.’s business
Merck & Co., Inc. is a global biopharmaceutical company involved in discovering, developing, manufacturing, and marketing healthcare products, operating in the Health Technology sector, specifically within the Pharmaceuticals: Major industry. Merck's business includes human health pharmaceutical products, vaccines, biologic therapies, and animal health products. The human health pharmaceutical segment offers therapeutic and preventive agents for various disorders, including oncology, infectious diseases, cardio-metabolic disorders, immunology, neuroscience, and ophthalmology. Key products include Keytruda, Gardasil, Welireg, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet. The Animal Health segment provides veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals, including brands like Nuflor, Bovilis/Vista, Bravecto, and Sentinel Spectrum. Merck also offers identification, traceability, and monitoring products for animals.
MRK’s Geographic footprint
Merck & Co., Inc. has a significant global presence with operations and research facilities worldwide. The company's primary geographic regions for revenue generation include the United States, Europe, Middle East and Africa (EMEA), China, Latin America, Japan, Asia Pacific (excluding China and Japan), and other international areas. The United States consistently represents the largest portion of its total revenue. Merck operates manufacturing facilities across North America, South America, Western Europe, Africa, and Asia.
MRK Corporate Image Assessment
Merck's brand reputation is generally associated with its long-standing commitment to scientific excellence, innovation, and improving global health through the development of medicines and vaccines. The company emphasizes its dedication to addressing unmet medical needs and its substantial impact on various therapeutic areas. Recent positive developments, such as successful clinical trial results for WINREVAIR™ and regulatory approvals for Keytruda, contribute positively to its reputation as a leader in biopharmaceutical innovation. No specific negative events significantly impacting Merck's brand reputation in the past year were found in the provided search results.
Ownership
Merck & Co., Inc. is predominantly owned by institutional shareholders, who collectively hold between 78.35% and 80% of the company's shares. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and State Street Corp. Vanguard Group Inc. is the largest individual shareholder, owning over 252 million shares, representing 10.13% of the company. Insiders hold a very small percentage of the company's stock, typically less than 1%, while retail investors account for approximately 21.43% of ownership.
Ask Our Expert AI Analyst
Price Chart
$84.70